NeonMind Appoints Trevor Millar as Chief Psychedelic Officer
NEONMIND APPOINTS TREVOR MILLAR as CHIEF PSYCHEDELIC OFFICER
Vancouver, B.C. – January 7, 2021: NeonMind Biosciences Inc. (CSE: NEON) (“NeonMind”), a
company conducting research into the potentially therapeutic uses of compounds found in
psychedelic mushrooms and commercializing medicinal mushroom products, is pleased to
announce that it has appointed Trevor Millar as Chief Psychedelic Officer of NeonMind as of
January 6, 2021.
Trevor Millar is a social‐entrepreneur who has played a key role in advancing the psychedelic
movement over the last eight years. Since May 2018 he has been on the board of directors for
the Multidisciplinary Association of Psychedelic Studies (MAPS) Canada, where he acted as
Chair of the Board for over two years. MAPS is a non‐profit organization and a leader in
supporting scientific research into psychedelics. He is also currently a board member and co‐
founder of the Canadian Psychedelic Association. From 2012 to 2017, Trevor was active as the
founder and President of Liberty Root Therapy Inc., a business dedicated to healing and
transformation by legally providing the plant medicine ibogaine to people with opiate use
disorder. Trevor was featured in the award‐winning documentary about using magic
mushrooms and Iboga to heal addiction, anxiety and depression called DOSED, which was
released in 2019.
“I’m very impressed with NeonMind’s psychedelic research plan and the experience of some of
their scientific team members as related to work studying substance use disorders,” says Trevor
Millar. “I’m excited about aligning NeonMind’s drug development plans with community needs.
There is tremendous suffering among the most marginalized people in society which
psychedelic drugs have the potential to heal, and I’m eager to build alliances for NeonMind that
benefit the community.”
As Chief Psychedelic Officer, Mr. Millar will assist NeonMind in several key areas:
● Developing policy
● Establishing multi‐party projects that use psychedelics to address community health
needs such as addiction
● Assisting NeonMind in developing safe and effective protocols for psychedelic
treatments for one or more human clinical trials to be submitted for approval to Health
Canada and
● Working within the psychedelic industry to build alliances and partnerships and to
identify potential acquisition targets for NeonMind
Trevor will continue his work as a director of MAPS and as a director of the Canadian
Psychedelic Association while devoting 80% of his professional time to his duties as Chief
Psychedelic Officer of NeonMind.
“Trevor Millar has immense experience in providing education about the risks and benefits of
psychedelics and has been a leader in the growth of the psychedelic industry,” says NeonMind
CEO Penny White. “We are honoured to welcome him to our management team to help
NeonMind develop our plan to legally and safely commercialize psychedelic drugs.”
Psychedelic research is continually unveiling potential therapeutic uses for psychedelic
compounds including treatment for depression, addiction and eating disorders. Data Bridge
Market Research analyses that the psychedelic drug market will reach USD 6.86 Billion by 2027.
About NeonMind Biosciences Inc.
NeonMind is developing and commercializing products that contain legal medicinal mushrooms
and products that may contain psychedelic compounds. Its first proposed drug candidate
involves the administration of psilocybin (a complex organic compound found in psychedelic
mushrooms) as a treatment for obesity and related illnesses for which NeonMind has started a
preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional
patent applications claiming methods of aiding in weight loss, treating compulsive eating
disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual
by administering psilocybin and/or other psychedelic compounds or their analogues or by
administering psilocybin or its analogue in conjunction with therapy or other treatments.
NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal
mushroom product formulas. It recently launched a collection of four mushroom‐infused
coffees containing medicinal mushrooms such as Lion’s Mane, Turkey Tail, Reishi and
Cordyceps. The NeonMind eCommerce platform launched in November 2020 at
www.neonmind.com for direct to consumer sales of these products.
For more information on NeonMind, go to www.NeonMindbiosciences.com or buy NeonMind
mushroom infused coffee at www.NeonMind.com.
Penny White, President & CEO
1‐866‐318‐6874
Investor Relations:
Edge Communications
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of
this news release.
Cautionary Statement Regarding Forward‐Looking Statements
Certain statements contained in this press release constitute forward‐looking information. These
statements relate to future events or NeonMind’s future performance. The use of any of the
words "could", "expect", "believe", "will", "projected","estimated" and similar expressions and
statements relating to matters that are not historical facts are intended to identify forward‐
looking information and are based on NeonMind’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind’s drug development plans, its ability to retain key personnel, and its
expectation as to the development of its intellectual property and other steps in its preclinical
and clinical drug development constitute forward‐looking information. Actual results and
developments may differ materially from those contemplated by forward‐looking information.
Readers are cautioned not to place undue reliance on forward‐looking information. The
statements made in this press release are made as of the date hereof. NeonMind disclaims any
intention or obligation to publicly update or revise any forward‐looking information, whether as
a result of new information, future events or otherwise, except as may be expressly required by
applicable securities laws.